← Therapy pipeline
Investigational · Obesity development

Zenagamtide

amycretin · NNC0487-0111 · Novo Nordisk

One molecule activates both GLP-1 and amylin receptors.

GLP-1amylin
Other study areas
Type 2 diabetesSleep apneaKnee osteoarthritisHeart failureWeight maintenance / switchingCardiovascular outcomes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorNovo Nordisk
TargetsGLP-1 + amylin
RouteInjection + Oral tablet
DevelopmentFormulations differ
01 / Evidence

Selected study results

Amycretin · dose escalation, Part BMean body-weight reductionBody weight decreased 24.3% · 36 weeks · Phase 1b/2a
Phase 1b/2a · Injection · Peer-reviewed results

Mean body-weight reduction · 36 weeks

Study focus: Weight management without type 2 diabetes

Investigational regimen
24.3%
Placebo / comparator
1.1%

Adults with overweight or obesity without diabetes; N is across all five trial parts · Subcutaneous escalation to 60 mg weekly vs placebo · Trial N=125 · Estimated mean change; published dose-escalation analysis. Results & methods ↗

Small early-phase cohorts and an escalation design. The result is not Phase 3 evidence or a result for the oral formulation.

Diabetes-focused studies

These studies evaluate people with type 2 diabetes; their results are separate from trials without diabetes.

Oral zenagamtide · Phase 2 type 2 diabetesHbA1c change · primary endpointHbA1c decreased 1.4 percentage points · 36 weeks · Phase 2
Phase 2 · Oral · Peer-reviewed results

HbA1c change · primary endpoint · 36 weeks

Study focus: Glycemic control in type 2 diabetes

HbA1c fell 1.4 percentage points at 50 mg; the estimated difference from placebo was 1.09 points.

Oral zenagamtide 50 mg
1.4 percentage points

Adults with type 2 diabetes receiving metformin, with or without an SGLT2 inhibitor · 50 mg once daily; placebo-controlled dose-finding study · Trial N=186 · Efficacy estimand; on-treatment data without rescue medication. Results & methods ↗ · Publication ↗

This is a diabetes trial, not an obesity weight-loss trial. The chart shows the active arm only; the abstract reports the placebo-adjusted difference rather than a separate placebo-arm mean.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylinTargeted
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 3AMAZE initiated
TabletOral tablet · Once daily
Phase 3AMAZE program initiated
Milestone → next

Latest: Phase 3 includes separate obesity, type 2 diabetes, sleep-apnea, knee-osteoarthritis, heart-failure, and maintenance studies.

Next: Results from the separate oral and injectable AMAZE programs, including weight management and obesity-related conditions.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies8 records

Phase 3

AMAZE 1

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with obesity or overweight; injectable zenagamtide versus placebo.

Phase 3

AMAZE 12

Weight maintenance
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Weight-loss maintenance in adults with obesity who reach target dose during a run-in period.

Phase 3

AMAZE 2

Weight management with type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with obesity or overweight and type 2 diabetes; weight-management outcomes.

Phase 3

AMAZE 5

Weight management with knee osteoarthritis
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with overweight or obesity and knee osteoarthritis; evaluates weight and pain outcomes.

Phase 3

AMAZE 6

Weight management with knee osteoarthritis
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with overweight or obesity and knee osteoarthritis; separate study from AMAZE 5.

Phase 3

AMAZE 7

Comparative weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Separate registered zenagamtide protocol. Registry recruiting; outcomes pending.

Phase 3

AMAZE 8

Comparative weight management with type 2 diabetes
Study: Active, not recruitingResults: No registry results posted yetStatus reviewed November 2026

Phase 3 comparison of zenagamtide with semaglutide in adults with overweight or obesity and type 2 diabetes. Registry lists 985 actual participants, actual start May 20, 2026 and primary relative body-weight change at week 84. Active, not recruiting per November 10 update; no results are posted.

Phase 1 studies1 record

Phase 1b/2a

Amycretin Phase 1b/2a · dose escalation, Part B

Weight management without type 2 diabetes
Study: CompletedResults: Peer-reviewed results shown aboveStatus reviewed September 2026

Published early dose-escalation study; the displayed 36-week Part B result is for subcutaneous treatment, not tablets.

Related conditions and outcomes

Phase 3 studies5 records

Phase 3

AMAZE 3

Sleep-apnea outcomes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with overweight or obesity and obstructive sleep apnea who are not treated with positive-airway-pressure therapy.

Phase 3

AMAZE 4

Sleep-apnea outcomes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with overweight or obesity and obstructive sleep apnea treated with positive-airway-pressure therapy.

Phase 3

AMBIENCE

Cardiovascular outcomes
Study: Planned / not yet recruitingResults: No registry results posted yetStatus reviewed November 2026

Separate registered zenagamtide protocol. Registry is not yet recruiting despite sponsor-reported program initiation; outcomes pending.

Phase 3

AMBITION 7

Glycemic control in type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Separate registered zenagamtide protocol. Registry recruiting; outcomes pending.

Phase 3

HF-POLARIS

Heart-failure outcomes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Morbidity and mortality in adults with obesity and HFpEF or HFmrEF.

Phase 2 studies1 record